Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI).
Khanna S, Sims M, Louie TJ, Fischer M, LaPlante K, Allegretti J, Hasson BR, Fonte AT, McChalicher C, Ege DS, Bryant JA, Straub TJ, Ford CB, Henn MR, Wang EEL, von Moltke L, Wilcox MH. Khanna S, et al. Among authors: wilcox mh. Antibiotics (Basel). 2022 Sep 10;11(9):1234. doi: 10.3390/antibiotics11091234. Antibiotics (Basel). 2022. PMID: 36140013 Free PMC article. Review.
Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.
Gerding DN, Cornely OA, Grill S, Kracker H, Marrast AC, Nord CE, Talbot GH, Buitrago M, Gheorghe Diaconescu I, Murta de Oliveira C, Preotescu L, Pullman J, Louie TJ, Wilcox MH. Gerding DN, et al. Among authors: wilcox mh. Lancet Infect Dis. 2019 Mar;19(3):265-274. doi: 10.1016/S1473-3099(18)30614-5. Epub 2019 Jan 29. Lancet Infect Dis. 2019. PMID: 30709665 Free article.
Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection.
Normington C, Moura IB, Bryant JA, Ewin DJ, Clark EV, Kettle MJ, Harris HC, Spittal W, Davis G, Henn MR, Ford CB, Wilcox MH, Buckley AM. Normington C, et al. Among authors: wilcox mh. NPJ Biofilms Microbiomes. 2021 Feb 5;7(1):16. doi: 10.1038/s41522-021-00184-w. NPJ Biofilms Microbiomes. 2021. PMID: 33547298 Free PMC article.
An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones.
Vehreschild MJGT, Ducher A, Louie T, Cornely OA, Feger C, Dane A, Varastet M, Vitry F, de Gunzburg J, Andremont A, Mentré F, Wilcox MH. Vehreschild MJGT, et al. Among authors: wilcox mh. J Antimicrob Chemother. 2022 Mar 31;77(4):1155-1165. doi: 10.1093/jac/dkab474. J Antimicrob Chemother. 2022. PMID: 35016205 Free PMC article. Clinical Trial.
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
Okhuysen PC, Ramesh MS, Louie T, Kiknadze N, Torre-Cisneros J, de Oliveira CM, Van Steenkiste C, Stychneuskaya A, Garey KW, Garcia-Diaz J, Li J, Duperchy E, Chang BY, Sukbuntherng J, Montoya JG, Styles L, Clow F, James D, Dubberke ER, Wilcox M. Okhuysen PC, et al. Clin Infect Dis. 2024 Jun 14;78(6):1462-1472. doi: 10.1093/cid/ciad792. Clin Infect Dis. 2024. PMID: 38305378 Free PMC article. Clinical Trial.
Clostridium difficile: biological therapies.
Martin J, Mawer D, Wilcox MH. Martin J, et al. Among authors: wilcox mh. Curr Opin Infect Dis. 2013 Oct;26(5):454-60. doi: 10.1097/01.qco.0000433319.82618.8f. Curr Opin Infect Dis. 2013. PMID: 23982236 Review.
469 results